# Semaglutide and Blood Eosinophils: A 371-Patient Before-and-After Study

Semaglutide and blood eosinophils in 371 adults | median counts fell from 160 to 110 per microliter and the share below 150 rose from 44.20% to 65.79%, with no asthma outcome measured.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/a-blood-marker-nobody-was-watching
Updated: 2026-11-14
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Semaglutide and Blood Eosinophils: A 371-Patient Before-and-After Study

Median eosinophil counts fell from 160 to 110 per microliter after people started semaglutide. The single-center study had no control group and measured no asthma outcome.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

Median blood eosinophil count, per µL · 160 · 110 · before · after · below 150/µL: · 44.2% · rose to · 65.8% · 371 patients, one clinic, no control group, no asthma outcome.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A retrospective single-center study looked at blood eosinophil counts in 371 adults before and after being prescribed semaglutide.
-   Median counts fell from 160 to 110 per microliter and the eosinophil percentage from 2.20% to 1.60% (both P < 0.001).
-   The share of people below the 150 per microliter threshold rose from 44.20% to 65.79%.
-   No asthma outcome was measured, and there was no control group.

Research on [GLP-1 drugs and asthma attacks](https://buythisglp.com/research/do-glp1-drugs-help-asthma) looks at whether patients have fewer exacerbations. This study asked a different question. A Shanghai clinic tracked eosinophil counts in people prescribed semaglutide [\[1\]](https://buythisglp.com/research/a-blood-marker-nobody-was-watching#ref-1). Clinicians use these white blood cells to help identify types of asthma and assess who may respond to certain biologic drugs.

Counts fell. The median went from 160 to 110 per microliter, the eosinophil percentage from 2.20% to 1.60%, and the proportion of people sitting below the commonly used 150 threshold rose from 44.20% to 65.79%. Reductions appeared in people who started above the threshold and in those who started below it.

Nobody's asthma was measured

This is a blood count study. It reports no symptoms, no exacerbations, no inhaler use and no lung function, so the clinical meaning of the fall is entirely inferred. There is also no control group: eosinophil counts move with season, infection, allergen exposure and steroid use, and a before-and-after comparison in one clinic cannot separate a drug effect from any of those.

The median percentage decline was 31.58% in the group with a BMI below 28 and 21.04% in the group at or above 28 (P = 0.037) [\[1\]](https://buythisglp.com/research/a-blood-marker-nobody-was-watching#ref-1). In the adjusted analysis, the starting eosinophil count was the only independent predictor of the decline. The study design leaves open how much of the change came from semaglutide, weight change or other factors.

## Frequently asked

Does semaglutide help asthma?

This study cannot say. It measured blood eosinophil counts and reported no symptoms, exacerbations, inhaler use or lung function, and had no control group.

Why would the eosinophil count matter?

It is used to phenotype asthma and to decide who is likely to respond to certain biologic treatments, so a drug that moves the count could affect how a specialist reads it.

Was the fall just from weight loss?

The study could not isolate the role of weight change. People in the lower-BMI group had a larger percentage decline, and the starting eosinophil count was the only independent predictor in the adjusted analysis.

## Sources

1.  \[1\] Wu Y, Lin Y, Wu J, Zhao L, Lin Y, Chen W, Zhu Y, Wang Y, Zhang M, Bao W (2026). Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study BMC Pulmonary Medicine. [PMID 42401898](https://pubmed.ncbi.nlm.nih.gov/42401898/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
